<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
      <PMID Version="1">35418819</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>15</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Print">1661-8769</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>13</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Feb</Month>
            </PubDate>
          </JournalIssue>
          <Title>Molecular syndromology</Title>
          <ISOAbbreviation>Mol Syndromol</ISOAbbreviation>
        </Journal>
        <ArticleTitle><i>KMT2B</i>-Related Dystonia: Challenges in Diagnosis and Treatment.</ArticleTitle>
        <Pagination>
          <StartPage>159</StartPage>
          <EndPage>164</EndPage>
          <MedlinePgn>159-164</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1159/000518974</ELocationID>
        <Abstract>
          <AbstractText>In this study, we report the first known Turkish case of a novel nonsense mutation c.2453dupT (p.M818fs*28) in the <i>KMT2B</i> (NM_014727.2) gene diagnosed in a male patient with <i>KMT2B</i>-related dystonia (DYT-<i>KMT2B</i>, DYT-28, Dystonia*-28), which is a complex, childhood-onset, progressive, hereditary dystonia. The patient, who is followed up from 9 to 13 years of age, had dysmorphic features, developmental delay, short stature, and microcephaly, in addition to focal dystonia and hemichorea (in the right and left lower extremities). Generalized dystonia involving bulbar and cervical muscles, in addition to dystonic cramps, myoclonus, and hemiballismus, were also observed during the course of the follow-up. While he was able to perform basic functions like eating, climbing stairs, walking, and writing with the aid of levodopa and trihexyphenidyl treatment, his clinical status gradually deteriorated secondary to progressive generalized dystonia in the 4-year follow-up. Deep brain stimulation has been shown to be effective in several patients which could be the next preferred treatment for the patient.</AbstractText>
          <CopyrightInformation>Copyright © 2021 by S. Karger AG, Basel.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Aksoy</LastName>
            <ForeName>Ayşe</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pediatric Neurology, Samsun Ondokuz Mayıs University, Samsun, Turkey.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yayıcı Köken</LastName>
            <ForeName>Özlem</ForeName>
            <Initials>Ö</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pediatric Neurology, Ankara City Hospital, Ankara, Turkey.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ceylan</LastName>
            <ForeName>Ahmet Cevdet</ForeName>
            <Initials>AC</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Molecular Biology and Genetics, Ankara City Hospital, Yıldırım Beyazıt University, Ankara, Turkey.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Toptaş Dedeoğlu</LastName>
            <ForeName>Özge</ForeName>
            <Initials>Ö</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pediatric Neurology, Mardin State Hospital, Ankara, Turkey.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D002363">Case Reports</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>17</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Mol Syndromol</MedlineTA>
        <NlmUniqueID>101525192</NlmUniqueID>
        <ISSNLinking>1661-8769</ISSNLinking>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Childhood dystonia</Keyword>
        <Keyword MajorTopicYN="N">Exome sequencing</Keyword>
        <Keyword MajorTopicYN="N">KMT2B</Keyword>
        <Keyword MajorTopicYN="N">Movement disorder</Keyword>
        <Keyword MajorTopicYN="N">Novel mutation</Keyword>
      </KeywordList>
      <CoiStatement>The authors have no conflicts of interest to declare.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>20</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>10</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pmc-release">
          <Year>2022</Year>
          <Month>8</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>14</Day>
          <Hour>5</Hour>
          <Minute>20</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35418819</ArticleId>
        <ArticleId IdType="pmc">PMC8928205</ArticleId>
        <ArticleId IdType="doi">10.1159/000518974</ArticleId>
        <ArticleId IdType="pii">msy-0013-0159</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Abela L, Kurian MA, KMT2B-Related Dystonia.   GeneReviews® [Internet] (University of Washington, Seattle 1993–2021) In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJ, Mirzaa G, et al., editors. Initial posting: 26 April 2018. </Citation>
        </Reference>
        <Reference>
          <Citation>Barbagiovanni G, Germain PL, Zech M, Atashpaz S, Lo Riso P, D'Antonio-Chronowska A, et al.  KMT2B Is Selectively Required for Neuronal Transdifferentiation, and Its Loss Exposes Dystonia Candidate Genes. Cell Rep. 2018;25:988–1001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6218204</ArticleId>
            <ArticleId IdType="pubmed">30355503</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carecchio M, Invernizzi F, Gonzàlez-Latapi P, Panteghini C, Zorzi G, Romito L, et al.  Frequency and phenotypic spectrum of KMT2B dystonia in childhood: A single-center cohort study. Mov Disord. 2019;34:1516–27.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31216378</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cif L, Demailly D, Lin JP, Barwick KE, Sa M, Abela L, et al.  KMT2B-related disorders: expansion of the phenotypic spectrum and long-term efficacy of deep brain stimulation. Brain. 2020;143:3242–61.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7719027</ArticleId>
            <ArticleId IdType="pubmed">33150406</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kawarai T, Miyamoto R, Nakagawa E, Koichihara R, Sakamoto T, Mure H, et al.  Phenotype variability and allelic heterogeneity in KMT2B-Associated disease. Parkinsonism Relat Disord. 2018;52:55–61.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29653907</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li XY, Dai LF, Wan XH, Guo Y, Dai Y, Li SL, et al.  Clinical phenotypes, genotypes and treatment in Chinese dystonia patients with KMT2B variants. Parkinsonism Relat Disord. 2020;77:76–82.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32634684</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zech M, Boesch S, Maier EM, Borggraefe I, Vill K, Laccone F, et al.  Haploinsufficiency of KMT2B, encoding the lysine-specific histone methyltransferase 2B, results in early-onset generalized dystonia. Am J Hum Genet. 2016;99:1377–87.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5142117</ArticleId>
            <ArticleId IdType="pubmed">27839873</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zech M, Lam DD, Winkelmann J. Update on KMT2B-Related Dystonia. Curr Neurol Neurosci Rep. 2019;19:92.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31768667</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
